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Background: Profound methylation of CpG islands constitutes a distinct molecular subtype of colorectal cancer
(CRC). The frequencies of methylation in CRC vary according to clinico-pathological characteristics including sex.
However, interaction between these characteristics and prognostic influence of methylation status has not been
clearly defined. We have investigated the prognostic role of promoter methylation using eight CpG island
methylator phenotype (CIMP) markers in 497 stage II or III CRC patients who underwent curative resection followed
by adjuvant FOLFOX. Overall survival (OS) and disease-free survival (DFS) were compared between subgroups
classified by methylation status, and interactions with clinico-pathological features were analyzed.
Results: CIMP-high (≥5 methylated loci) and concurrent methylation in NEUROG1 and CDKN2A (p16) were found in
5.8 and 7.9 % of patients, respectively. Although CIMP-high status was not associated with survival, concurrent
methylation in NEUROG1 and CDKN2A (p16) was associated with shorter OS and DFS. Moreover, the prognostic role
of the concurrent methylation was different among sex. The negative prognostic impact was only observed in male
but not in female (interaction p value = 0.026 for OS and 0.011 for DFS). In male, the 5-year OS was 61.6 % in
concurrent methylation (+) and 91.7 % in concurrent methylation (−) (p < 0.001) whereas it was 95.0 and 92.8 % in
female, respectively (p = 0.78).
Conclusions: Concurrent methylation in NEUROG1 and CDKN2A is associated with poor survival in CRC treated with
adjuvant FOLFOX. Interaction analysis indicates that the prognostic role is different according to sex.
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Colorectal cancer develops through various types of gen-
etic and epigenetic alterations, and several critical genes
and pathways underlying the carcinogenesis have been
elucidated. Most notably, at least three distinct pathways
have generally been accepted, the chromosomal instabil-
ity (CIN), microsatellite instability (MSI), and CpG is-
land methylator phenotype (CIMP) pathways. CIMP is
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have distinct features compared to CIN cancers that they
are more frequently observed in proximal location, older
and female patients, and have poor pathologic differenti-
ation [1–3].
There have been controversies in the prognostic role
of CIMP in colorectal cancer patients [3–8]. The incon-
sistency may be related to CIMP definition using differ-
ent methylation markers and confounding role of other
molecular alterations such as MSI or BRAF mutation.
The prognostic implication of CIMP could also be differ-
ent according to tumor locations [8, 9]. Moreover,
methylation status of individual genes may be more im-
portant than the number of methylated markers inle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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concurrent methylation in NEUROG1 and CDKN2A (p16)
is associated with higher recurrence in colorectal cancer
patients whereas CIMP classification based on the number
of methylated markers was not [4]. Importance of individ-
ual gene methylation such as CHFR, MGMT, and SHISA3
has also been shown in other studies [6, 10, 11].
Sex influences clinico-pathological characteristics of
colorectal cancer. Male has a higher age-adjusted colo-
rectal cancer incidence and death rate compared to fe-
male [12, 13]. The proportion of proximal cancer is
higher in female whereas distal colon and rectal cancer
is more frequent in male [14]. CIMP also has sexual dif-
ference that the frequency is higher in female [1]. The
etiology for the sex difference remains uncertain while
hormonal factor, dietary factor, and lifestyle factor have
been suggested as the cause [15–17].
In the present study, we have analyzed the impact of
methylation status on survival in 497 stage III or high-
risk stage II colorectal cancer patients treated with adju-
vant FOLFOX chemotherapy. We have further investi-
gated whether the prognostic implication is different




A total of 497 patients were included in the present
study. Baseline characteristics are summarized in Table 1.
Tumor location was cecum in 18, ascending colon in
113, transverse in 39, descending in 31, sigmoid in 264,
and rectum in 32 patients. Collectively, 169 patients had
tumor in proximal (from cecum to transverse colon) lo-
cation and 328 patients had tumor in distal location.
Tumor stage was stage II in 74 patients (IIA in 49, IIB in
21, and IIC in 4) and stage III in 423 patients (IIIA in
39, IIIB in 273, and IIIC in 111). All stage II patients had
high-risk features. Microsatellite instability (MSI-high)
was shown in 6.5 % of tumors. According to the inclu-
sion criteria, all patients received at least 6 cycles of
chemotherapy and 89.9 % of patients completed planned
12 cycles of chemotherapy.
Methylation status
Methylation at one or more loci was observed in 181 pa-
tients (36.4 %, Table 2). CRABP1 was the most fre-
quently methylated locus, followed by NEUROG1 and
CDKN2A (p16). Twenty-nine patients (5.8 %) had tu-
mors with five or more methylated loci (CIMP-high),
152 patients (30.6 %) had one to four methylated loci
(CIMP-low), and 316 patients (63.6 %) had no methyl-
ated locus (CIMP-negative). Patients with CIMP-high tu-
mors were designated the CIMP(+), and those with
CIMP-low or CIMP-negative tumors were designatedthe CIMP(−). Patients with following characteristics had
higher incidence of CIMP(+): female sex, proximal
tumor location, mucinous adenocarcinoma histology,
MSI-high, and BRAF mutation (Table 1). CIMP(+) tu-
mors had a tendency of lower incidence in obese pa-
tients (BMI >25 kg/m2 for Asian) compared to CIMP(−)
(p = 0.096). Incidence of CIMP(+) and individual gene
methylation was similar among age.
We previously reported that concurrent methylation
in NEUROG1 and CDKN2A (p16) was associated with
higher recurrence [4]. Concurrent methylation in NEU-
ROG1 and CDKN2A (p16) was found in 39 patients
(7.9 %). Similar to CIMP(+), concurrent methylation had
higher incidence in patients with proximal tumor loca-
tion, mucinous adenocarcinoma histology, MSI-high,
and BRAF mutation. Although statistically not significant,
concurrent methylation had a tendency of higher in-
cidence in patients with female sex (51.3 vs. 38.4 %,
p = 0.115). In addition, N2 stage was higher in pa-
tients with concurrent methylation in NEUROG1 and
CDKN2A (p16) (41.0 vs. 25.5 %, p = 0.036). Incidence
of obesity was similar regardless of the concurrent
methylation status (25.6 % in patients with concur-
rent methylation vs. 35.8 % in patients without con-
current methylation, p = 0.20).
Prognosis according to methylation status
After a median follow-up duration of 65 months, the
5-year overall survival (OS) of the entire cohort was
91.1 % and the 3-year disease-free survival (DFS) was
87.2 %. There was no significant difference in OS or
DFS according to the CIMP status: the 5-year OS was
89.7 % in the CIMP(+) and 91.1 % in the CIMP(−) (p =
0.28, Fig. 1a) (DFS, Fig. 1b). There was no difference in
the pattern of recurrence (local recurrence vs. distant
metastasis) according to the CIMP status.
We next evaluated the influence of concurrent methyla-
tion in NEUROG1 and CDKN2A (p16) on survival. Con-
current methylation in NEUROG1 and CDKN2A (p16)
was associated with poor OS and DFS (Fig. 1c) (DFS,
Fig. 1d). The 5-year OS was 78.9 % in patients with con-
current methylation in NEUROG1/CDKN2A (p16) and
92.1 % in patients without concurrent methylation in
NEUROG1/CDKN2A (p < 0.001). Multivariate analysis
using the Cox proportional hazard model revealed that
concurrent methylation in NEUROG1 and CDK2NA (p16)
was an independent negative prognostic factor for OS (ad-
justed hazard ratio (HR) for OS 2.89, 95 % confidence
interval (CI) 1.45–5.76, p = 0.002) but not for DFS.
Interaction between methylation status and
clinico-pathological factors
We next assessed whether the detrimental effect of con-
current methylation in NEUROG1 and CDKN2A (p16)
Table 1 Baseline characteristics
Total CIMP-negative CIMP-low CIMP-high p value*
N (%) N (%) N (%) N (%)
Total 497 (100) 316 (63.6) 152 (30.6) 29 (5.8)
Age
<65 years 348 (70.0) 222 (70.3) 108 (71.1) 18 (62.1) 0.34
≥65 years 149 (30.0) 94 (29.7) 44 (28.9) 11 (37.9)
Sex
Male 301 (60.6) 201 (63.6) 88 (57.9) 12 (41.4) 0.029
Female 196 (39.4) 115 (36.4) 64 (42.1) 17 (58.6)
Location
Proximal 169 (34.0) 87 (27.5) 61 (40.1) 21 (72.4) <0.001
Distal 328 (66.0) 229 (72.5) 91 (59.9) 8 (27.6)
BMI
<25 kg/m2 323 (65.0) 197 (62.3) 103 (67.8) 23 (79.9) 0.096
≥25 kg/m2 174 (35.0) 119 (37.7) 49 (32.2) 6 (20.7)
T stage
T1–3 424 (85.3) 274 (86.7) 128 (84.2) 22 (75.9) 0.14
T4 73 (14.7) 42 (13.3) 24 (15.8) 7 (24.1)
N stage
N0–1 364 (73.2) 228 (72.2) 116 (76.3) 20 (69.0) 0.59
N2 133 (26.8) 88 (27.8) 36 (23.7) 9 (31.0)
Tumor stage
II, high-risk 74 (14.9) 48 (15.2) 21 (13.8) 5 (17.2) 0.71
III 423 (85.1) 268 (84.8) 131 (86.2) 24 (82.8)
Histology
MAC 25 (5.0) 7 (2.2) 12 (7.9) 6 (20.7) <0.001
Non-MAC 472 (95.0) 309 (97.8) 140 (92,1) 23 (79.3)
Microsatellite status (N = 495)
MSS/MSI-L 463 (93.5) 306 (97.5) 138 (90.8) 19 (65.5) <0.001
MSI-H 32 (6.5) 8 (2.5) 14 (9.2) 10 (34.5)
KRAS mutation (N = 383)
Wild type 280 (73.1) 185 (76.4) 77 (64.2) 18 (85.7) 0.18
Mutation 103 (26.9) 57 (23.6) 43 (35.8) 3 (14.3)
BRAF mutation (N = 423)
Wild type 407 (96.2) 270 (99.3) 122 (93.8) 15 (71.4) <0.001
Mutation 16 (3.8) 2 (0.7) 8 (6.2) 6 (28.6)
N number, MAC mucinous adenocarcinoma, MSS microsatellite stable, MSI-L microsatellite instability-low, MSI-H microsatellite instability-high
*p values comparing CIMP-high vs. CIMP-low/CIMP-negative by chi-square test
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including sex (Fig. 2). The prognostic role of concurrent
methylation in NEUROG1 and CDKN2A (p16) was dif-
ferent among sex (interaction p value for OS = 0.026, for
DFS = 0.011). It was associated with significantly worse
OS and DFS in men (Fig. 3a) (DFS, Fig. 3c). However,
there was no prognostic role of concurrent methylation
in women (Fig. 3b) (DFS, Fig. 3d). In the multivariateanalysis, the poor prognosis associated with concurrent
methylation in NEUROG1 and CDKN2A (p16) in male
was independent of other clinico-pathologic prognostic
factors (adjusted HR for OS 5.23, 95 % CI 2.45–11.17,
p < 0.001) (adjusted HR for DFS 3.66, 95 % CI 1.82–7.36,
p < 0.001) (Table 3). Other clinico-pathological factors,
including tumor location, did not affect the prognostic
role of concurrent methylation in NEUROG1 and









0 316 (63.6) CACNA1G 41 (8.2)
1 94 (18.9) CRABP1 98 (19.7)
2 37 (7.4) IGF2 30 (6.0)
3 13 (2.6) MLH1 18 (3.6)
4 8 (1.6) NEUROG1 87 (17.5)
5 13 (2.6) CDKN2A
(p16)
85 (17.1)
6 9 (1.8) RUNX3 29 (5.8)
7 4 (0.8) SOCS1 22 (4.4)
8 3 (0.6)
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we could not sub-analyze patients according to BRAF
mutation or MSI status.
Discussion
In the present study, we have investigated the impact of
promoter methylation on treatment outcome of colo-
rectal cancer patients receiving adjuvant FOLFOX
chemotherapy. As all patients in our cohort were Korean,Fig. 1 Kaplan-Meier curves of overall survival and disease-free survival accordi
(p16) (c, d). Co-methylation concurrent methylation, N numberour data shows relatively low incidence of MSI-high
(MSI-H) and CIMP-high. Previous studies using stan-
dardized methodologies have repeatedly shown that the
Western shows higher incidence of MSI-H and CIMP-
high compared to the Eastern [18]. We observed that
CIMP-high is not associated with survival, but concurrent
methylation in NEUROG1 and CDKN2A (p16) has dele-
terious effect in terms of OS and DFS. In addition, the
prognostic role of concurrent methylation in NEUROG1
and CDKN2A was different among sex; it was a negative
prognostic factor in men but not in women (interaction
p value of 0.026 for OS and 0.011 for DFS).
Although the prognostic role of CIMP has been exten-
sively investigated in colorectal cancer patients, previous
studies have yielded inconsistent results. In the study by
Min et al., CIMP-high was a positive prognostic factor in
stage II or III colorectal cancer patients treated with
fluoropyrimidine-based adjuvant chemotherapy [7]. How-
ever, CIMP-high was a negative prognostic factor in stage
III, proximal colon cancer patients [8]. These inconsistent
results may have attributed from the heterogeneous
cohort of patients included in the study, different
CIMP-high definitions among studies and confounding
role of other molecular characteristics (MSI-high, KRASng to CIMP status (a, b) and concurrent methylation of NEUROG1/CDKN2A
Fig. 2 Forest plot demonstrating the risk of death by concurrent methylation (+) compared to concurrent methylation (−) stratified by
clinico-pathological factors. All hazard ratios were adjusted by histology, angiolymphatic invasion, and perineural invasion. N number, HR hazard
ratio, CI confidence interval, WT wild type, MT mutation type
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evidences that each methylation locus differs in their asso-
ciation with survival and clinico-pathological characteris-
tics. Concurrent promoter methylation in NEUROG1 and
CDKN2A (p16) was associated with poor DFS in stages II
and III colorectal cancer patients, and CHFR promoter
methylation indicated poor prognosis in stage II colorectal
cancer patients [4, 6]. In contrast, considerable proportion
of MSI-H in sporadic colorectal cancer results from the
loss of MLH1 expression by methylation of its promoter,
and it is known that MSI-H is associated with better prog-
nosis [19, 20]. In our study, CIMP-high was not associated
with survival but concurrent methylation in NEUROG1
and CDKN2A (p16) was associated with poor survival.
NEUROG1 is a transcription factor involved in neuronal
development and differentiation, and CDKN2A (p16) is a
tumor suppressor that inhibits cyclin-dependent kinases
CDK4 and CDK6 [21, 22]. Although the functional role of
promoter methylation in NEUROG1 and CDKN2A (p16)
is inconclusive, CDKN2A (p16) promoter methylation was
associated with poor survival in stages II and III colorectal
cancer patients who received adjuvant fluoropyrimidine-
based chemotherapy [23]. Classifying CIMP according to
the number of methylated loci may be useful for grouping
patients with similar clinico-pathological characteristics;
however, each promoter methylation may have different
prognostic roles, and thus, identifying each methylation
locus may be useful in the practice.There are sex differences in colorectal cancer inci-
dence, death rate, and clinico-pathological characteristics
[24]. Female colorectal cancer patients tend to have
CIMP-high and proximal tumor location compared to
male patients. To our knowledge, no study has revealed
the interaction between sex and prognostic impact of
promoter methylation yet. In this study, we found that
the prognostic role of concurrent methylation in NEU-
ROG1 and CDKN2A (p16) was influenced by sex. It was
associated with poor prognosis only in male patients.
Previous studies have shown that a negative prognostic
role of obesity has sex-related differences [15, 25]. How-
ever, we could not find association between methylation
status and obesity. Because of the retrospective nature of
this study, we could not examine other potential mechan-
ism underlying the sex differences including hormonal
factor, dietary factor, and lifestyle factor. Future prospect-
ive cohort study may provide answers to the differences.
Other limitation of this study is that only patients treated
with adjuvant FOLFOX were included. Therefore, we can-
not answer whether the poor prognosis of patients with
concurrent methylation in NEUROG1 and CDKN2A (p16)
is due to its innate biology or its resistance to adjuvant
chemotherapy regimen. However, the major strength of
the study is that the study cohort was homogenous, that
all patients underwent surgery at a high-volume center
and received the same adjuvant FOLFOX chemotherapy,
which is the current standard care in patients with stage
Fig. 3 Kaplan-Meier curves of overall survival (OS) and disease-free survival (DFS) according to concurrent methylation of NEUROG1/CDKN2A (p16)
stratified by sex. (a) Male: OS. (b) Female: OS. (c) Male: DFS. (d) Female: DFS. Co-methylation concurrent methylation, N number
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ation in an independent cohort of patients.
Conclusions
While CIMP is well known for its role in colon cancer
tumorigenesis, the prognostic role of CIMP has not been
well defined. In this study, CIMP-high did not have aTable 3 Multivariate analysis of overall survival and disease-free surv
Overall survival
Adjusted HR (95 %
Concurrent methylation Present 5.23 (2.45–11.1
Not present 1
Angiolymphatic invasion Present 4.41 (1.97–9.85
Not present 1
Age (continuous variable) 1.032 (0.99–1.0




CI confidence interval, MAC mucinous adenocarcinomaprognostic role; however, concurrent methylation in
NEUROG1 and CDKN2A (p16) was independently asso-
ciated with poor survival in colorectal cancer patients
treated with adjuvant FOLFOX. In addition, the prog-
nostic role of concurrent methylation in NEUROG1 and
CDKN2A (p16) was influenced by sex. A negative prog-
nostic role of promoter methylation was shown in menival among male patients (N = 301)
Disease-free survival
CI) p value Adjusted HR (95 % CI) p value
7) <0.001 3.66 (1.82–7.36) <0.001
1
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ism that results in sex difference is warranted in the
future.
Methods
Patients and adjuvant chemotherapy
This study included 497 pathologically proven stage III
or high-risk stage II colorectal cancer patients who re-
ceived curative surgery followed by adjuvant FOLFOX
chemotherapy at Seoul National University Hospital
(SNUH; Seoul, Korea) between April 2005 and Decem-
ber 2011. Main inclusion criteria for the retrospective
patient selection were age over 18, adenocarcinoma hist-
ology, stage III or high-risk stage II, complete resection
of the tumor with negative margin, completion of at
least 6 cycles of adjuvant FOLFOX chemotherapy.
High-risk stage II was defined if the patient had any of
the following: T4 lesion, obstruction or perforation,
lymphovascular invasion, perineural invasion, or poorly
differentiated histology [27]. Patients with upper rectal
cancer were included if the patient did not receive pre-
or post-operative radiation. Patients were excluded if
they met the following criteria: previous chemotherapy
for colorectal cancer (CRC), previous radiotherapy for
CRC, signet ring cell histology, distant metastasis, and
history of other malignancy within 5 years. None of the
patients received anti-EGFR or anti-VEGF treatment ad-
junct to FOLFOX. Patient received FOLFOX chemo-
therapy as either FOLFOX-4 (288 patients) or modified
FOLFOX-6 (209 patients) regimen [28]. Adjuvant chemo-
therapy was planned for a total of 12 cycles.
Patients were assessed every 2 weeks during chemo-
therapy treatment and then at least every 6 months for
5 years. The post chemotherapy period assessment in-
cluded a medical history taking, physical examination,
measurement of the carcinoembryonic antigen level,
chest computed tomography, and abdominal computed
tomography. The diagnosis of recurrence was made on
the basis of imaging and, if necessary, biopsy.
Eligible patients were identified from electronic data-
base, and chart review was performed using the elec-
tronic medical record system of SNUH. The study
protocol was reviewed and approved by the institutional
review board of SNUH.
Molecular pathologic analysis
Analysis of DNA methylation and microsatellites was
performed as previously described [4, 29]. All patients
(N = 322) included in the previous report were included
in the present study [4]. DNA methylation analysis was
re-performed for these patients concurrently with the
new patients (N = 175). In brief, tumor tissue slides were
reviewed and areas of high tumor cell density (~1 cm2)
were marked and dissected with a knife blade. Non-neoplastic colon mucosa tissues were also dissected. The
dissected tumor tissues were collected into a microtube
containing tissue lysis buffer and proteinase K. Manual
microdissection was performed to enrich tumor cell
DNA proportion in the sample DNA, because the results
of quantitative MethyLight analysis may be influenced
by high proportions of contaminating normal cells. After
sodium bisulfite conversion of DNA using the EZ DNA
methylation kit (Zymo Research, Orange, CA, USA), the
methylation status was quantified using MethyLight
assay in the following eight CIMP markers: CACNA1G,
CDKN2A (p16), CRABP1, IGF2, MLH1, NEUROG1,
RUNX3, and SOCS1. The primer sequences and polymer-
ase chain reaction (PCR) conditions have been described
previously [29, 30]. M.SssI-treated genomic DNA was
used as a reference sample. Percentage of methylated ref-
erence (PMR) at a particular locus was calculated by divid-
ing the GENE/ALU ratio of a patient sample by the
GENE/ALU ratio of the M.SssI-treated human genomic
DNA sample and multiplying by 100. MethyLight assay
was repeated in triplicate, and of the three measured
values, the median was regarded as a representative value
of methylation level of each marker. A CpG island locus
with PMR >4 was considered to be methylated [4, 29, 31].
CIMP status was defined according to the number of
methylated markers: CIMP-high (methylation at ≥5
markers), CIMP-low (1–4 markers), or CIMP-negative
(0 marker) [4, 29, 31].
The microsatellite status of each tumor was deter-
mined by evaluating the five microsatellite markers
(D2S123, D5S346, D17S250, BAT25, and BAT26). Either
forward or reverse primer for each marker was labeled
with fluorescence, and PCR products were electropho-
resed and analyzed. We classified MSI status as follows:
MSI-high (MSI-H; instability at two or more microsatel-
lite markers), MSI-low (MSI-L; instability at one
marker), or microsatellite stable (MSS) (no instability).
Only MSI-H was regarded as having MSI, and MSI-L
was grouped with MSS [4, 32].
Analysis of KRAS and BRAF mutation was performed
as previously described [32]. DNA was extracted from
paraffin-embedded tissue, and KRAS mutation (codon
12 and 13 of exon 2) was analyzed by using hemi-nested
PCR method followed by direct sequencing. BRAF muta-
tions at codon 600 (V600E) were analyzed by using a
real-time PCR-based allelic discrimination method [32].
Statistical analysis
The primary objective of this study was to investigate
the effect of promoter methylation status on the treat-
ment outcome (OS and DFS) and their association with
sex in colorectal cancer patients treated with adjuvant
FOLFOX chemotherapy. The clinical database was last
updated in October 2014. DFS was calculated from the
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rence or death. Data from patients who were free of re-
currence were censored at the date of the last follow-up
visit for DFS. In the analysis of OS, death from any cause
was the primary end point. Categorical variables were
compared using the chi-square test. OS and DFS were
calculated using the Kaplan-Meier method, and compar-
isons were made using the log-rank tests. HR was calcu-
lated using the Cox proportional hazard model, and
baseline characteristics were adjusted by using backward
stepwise model including covariates which have the
prognostic role: age (continuous variable), sex, stage
(II vs. III), histology (mucinous adenocarcinoma vs.
others), tumor location (proximal vs. distal), angiolym-
phatic invasion, venous invasion, perineural invasion,
and MSI status. Two-sided p values of less than 0.05
were considered statistically significant. Statistical ana-
lysis was performed with SPSS software for Windows,
version 18.0 (SPSS, Chicago, IL, USA).
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